Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial

Liakos, Aris; Lambadiari, Vaia; Bargiota, Αlexandra; Kitsios, Konstantinos; Avramidis, Iakovos; Kotsa, Kalliopi; Gerou, Spyridon; Boura, Panagiota; Tentolouris, Nikolaοs; Dimitriadis, George

doi:10.1111/dom.13541

Cited by 28 publications

(39 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta-analysis suggested that blood pressure lowering in early ischemic stroke had a neutral effect on the prevention of death or dependency [50]. Evidence for Cardiovascular Prevention from Observational Cohorts in Japan showed SBP was positively associated with ischemic stroke and intraparenchymal hemorrhage death [51].…”

Section: Discussionmentioning

confidence: 99%

The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis

Nie

Zhang

2020

Lipids Health Dis

View full text Add to dashboard Cite

Background: Fermented milk has over the last decade been intensively studied because of the putative antihypertensive effect. The aim of our study is to investigate the role of probiotics support therapy in blood pressure and, as a kind of convenient and economic drugs for prevention and auxiliary treatment of hypertension. Materials and methods: We performed a systemic review and meta-analysis to examine the effect of probiotics consumption on blood pressure. Databases including MEDLINE, EMBASE, Clinical trials, CNKI and the Cochrane library were searched. Also, the grey literature and references were searched. Results: Twenty-three randomized controlled trials (RCTs) involving 2037 participants met the inclusion criteria and were included. Probiotic consumption significantly changed systolic blood pressure (SBP) by − 3.05 mmHg (95%CI: − 4.67, − 1.44; P < 0.001) and diastolic blood pressure (DBP) by − 1.51 mmHg (95%CI: − 2.38, − 0.65; P = 0.001). Subgroup analysis indicated that the benefit effect of probiotics supplementation in SBP was only observed in hypertension [weight mean difference (WMD) = − 3.31 mmHg, 95%CI: − 5.71, − 0.92; P = 0.007] or type 2 diabetes (WMD =-4.85 mmHg, 95%CI: − 9.28, − 0.42; P = 0.032) patients, and the decreased DBP level by probiotics supplementation was only observed in hypertension patients (WMD =-2.02 mmHg, 95%CI: − 3.68, − 0.36; P = 0.017).This effect could only last for a short-term time of 8 or 10 weeks, but not for a long-term time. Conclusion: This meta-analysis found a moderate and statistically significant reduction for either SBP or DBP with probiotics supplement compared with controls. Thus, probiotics is a potential for the dietary treatment of hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis

Nie

Zhang

2020

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…These differences in blood pressure were much higher in our study than reported in LEAD studies that showed a reduction of systolic blood pressure between 2.7 and 2.9 mmHg [ 9 - 13 ]. Another randomized controlled trial analyzed the effect of liraglutide on blood pressure and compared it with placebo, showing a reduction in systolic blood pressure by -5.73 mmHg and a neutral effect on diastolic blood pressure by a mean difference of -1.42 mmHg [ 18 ]. Interestingly, a real-world evidence study from India showed a systolic blood pressure reduction of 9.7 mmHg, which was similar to that in our study [ 19 ].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients

Zameer¹,

Kamin²,

Raja³

et al. 2020

Cureus

View full text Add to dashboard Cite

Background and Objectives Liraglutide, an analog of human glucagon-like peptide 1 (GLP-1), has been approved for the treatment of type 2 diabetes mellitus in Pakistan since 2016. It is a GLP-1 receptor agonist that has shown promising results in terms of not only glycemic control but also weight loss. Our study aimed to provide evidence regarding the safety and effectiveness of liraglutide in Pakistan and to look at the adherence rate and treatment satisfaction of patients using liraglutide. Methods This is an observational retrospective study that recruited patients who were treated with liraglutide. Data were collected at the first visit and follow-up. Morisky Green Levine Adherence Scale and Treatment Satisfaction Questionnaire for Medication (TSQM-9) were used for the determination of adherence and satisfaction with the treatment. Results A total of 70 patients were recruited in the study, The mean difference in weight, body mass index, glycated hemoglobin (HbA1C), systolic blood pressure, and diastolic blood pressure from baseline to follow-up was -5.36 kg, -2.14 kg/m 2 , -1.76%, -12.38 mmHg, and 5.55 mmHg, respectively. Nausea was the main side effect reported. TSQM-9 scores were compared from baseline, and it was found that patients are satisfied with the treatment and its effectiveness. Conclusions Our study has demonstrated the effectiveness of liraglutide as a monotherapy or combination therapy in the Pakistani population. Liraglutide led to reduction in HbA1C and weight. This is associated with high treatment satisfaction rate and adherence rate. Thus, liraglutide remains an effective though expensive treatment option in a country like Pakistan.

show abstract

“…Again, liraglutide caused a significant increase in the mean 24-hour heart rate by 6.16 beats/min. Of note, the beneficial effect of liraglutide on the 24-hour blood pressure was not associated with an increase in urine sodium excretion (44).…”

Section: Liraglutidementioning

confidence: 85%

Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects

Montan¹,

Sourlas²,

Olivero³

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

Obesity is a chronic, relapsing, multifactorial disease, which has become a serious threat to public health globally, as the worldwide prevalence of obesity increases exponentially over time. It has been well established that obesity is associated with multiple adverse cardiometabolic effects. Although lifestyle changes are the first line of therapy for obesity, these are often insufficient in attaining weight loss goals.Orlistat, phentermine/topiramate, lorcaserin, naltrexone/bupropion, and liraglutide are agents that have been approved for the treatment of obesity but their effects on cardiometabolic risk factors and outcomes have not been clearly elucidated. Given the detrimental repercussions of obesity on cardiometabolic health, there is a pressing clinical need to fully understand the effects of these agents beyond weight loss alone. Certain previous weight loss drugs have been withdrawn due to safety concerns and this underlines the need for more careful assessment of the effects of the various pharmacologic agents currently used for the treatment of obesity. This review aims to provide an overview of the mechanisms, efficacy, safety and cardiometabolic effects of the currently available pharmacologic agents for weight loss.

show abstract

Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial

Cited by 28 publications

References 31 publications

The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis

The effect of probiotics supplementation on blood pressure: a systemic review and meta-analysis

Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients

Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects

Contact Info

Product

Resources

About